Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -184.04% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-184.04%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.15%
median of 596 covered companies
CURRENT VS SECTOR MEDIAN
-358.45%
vs the sector median at left
20/20 Biolabs Inc.
Market Cap
$4.20M
Return on Equity (ROE)
-184.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.13M
Return on Equity (ROE)
N/A
TTM Avg
-201.28%
3Y Avg
-1309.54%
5Y Avg
-838.52%
Market Cap
$4.12M
Return on Equity (ROE)
N/A
TTM Avg
-470.92%
3Y Avg
-382.96%
5Y Avg
-276.61%
Market Cap
$4.33M
Return on Equity (ROE)
-424.89%
TTM Avg
-156.14%
3Y Avg
-97.37%
5Y Avg
-86.32%
Market Cap
$4.05M
Return on Equity (ROE)
-437.15%
TTM Avg
-328.44%
3Y Avg
-188.67%
5Y Avg
-533.64%
Market Cap
$4.03M
Return on Equity (ROE)
-383.03%
TTM Avg
-1602.50%
3Y Avg
-1094.59%
5Y Avg
-783.90%
Market Cap
$4.40M
Return on Equity (ROE)
-54.15%
TTM Avg
0.37%
3Y Avg
-1.09%
5Y Avg
-10.37%
Market Cap
$4.55M
Return on Equity (ROE)
-239.95%
TTM Avg
-454.28%
3Y Avg
-297.70%
5Y Avg
-194.53%
Market Cap
$4.69M
Return on Equity (ROE)
-30.74%
TTM Avg
235.96%
3Y Avg
-836.91%
5Y Avg
-570.34%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 20/20 Biolabs Inc. (AIDX) | $4.20M | -184.04% | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.13M | N/A | -201.28% | -1309.54% | -838.52% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.12M | N/A | -470.92% | -382.96% | -276.61% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.33M | -424.89% | -156.14% | -97.37% | -86.32% |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.05M | -437.15% | -328.44% | -188.67% | -533.64% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.03M | -383.03% | -1602.50% | -1094.59% | -783.90% |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.40M | -54.15% | 0.37% | -1.09% | -10.37% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | -239.95% | -454.28% | -297.70% | -194.53% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.69M | -30.74% | 235.96% | -836.91% | -570.34% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.79M | -163.18% | -235.11% | -195.15% | -161.13% |
ROE
-184.0%
ROA
-95.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -184.04% |
